MedTrace Logo

PRecision Oncology Evidence Development in Cancer Treatment - Liquid

NCT05057234 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2025-09-25

No results posted yet for this study

Summary

The current standard of care for molecular characterization of tumors is tissue based next generation sequencing (NGS) panel. Liquid biopsies (ie blood) are of increasing interest and have been implemented as a diagnostic tool in some countries. This study compares tissue based and liquid based testing to evaluate the detection rate and cost consequence of using this new tool in BC.

Conditions

Interventions

DIAGNOSTIC_TEST

FoundationOne liquid CDx

FoundationOne liquid CDx testing

BEHAVIORAL

Quality of life questionnaires

Quality of life questionnaire - EQ5D

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Cheryl Ho, MD · BC Cancer

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-18
Primary Completion
2027-06-01
Completion
2027-06-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05057234 on ClinicalTrials.gov